Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Sumit Garg, ASCRS 2021: Pterygia – Clinical Characteristics and Surgical Risks

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 23rd 2021

It was a pleasure to catch up with Sumit Garg (Gavin Herbert Eye Institute, University of California, Irvine, CA, USA), who spoke about the clinical characteristics of pterygium, the risks of surgical removal and improved outcomes from conjunctival autograft, adjunctive amniotic membrane transplantation and intraoperative mitomycin C.

Questions

  1. Could you give us a brief overview of pterygium and its clinical characteristics? (00:22)
  2. What are the risks of the surgical removal of a pterygium? (00:52)
  3. How have conjunctival autograft, adjunctive amniotic membrane transplantation and intraoperative mitomycin C, improved outcomes? (01:32)

Speaker Disclosure: Sumit Garg has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of ASCRS 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup